3DBio Therapeutics, founded with a mission to revolutionize regenerative medicine, specializes in precision bioprinting of living tissues. The company aims to replace individual patient parts with custom-designed tissues, leveraging advanced bioprinting technologies. Their core products and services include the GMPrint™ and ColVivo™ platforms, which are designed for the precise manufacturing of biologically compatible tissues. 3DBio focuses on the healthcare market, particularly in areas requiring tissue regeneration and repair.
Notable figures affiliated with 3DBio include experts in bioprinting and regenerative medicine, although specific names are not provided. The company has attracted significant investment from key players in the biotech industry. Among its achievements, 3DBio has developed proprietary cell processes and clinically tested bioprinting technologies that have shown promise in preclinical and clinical settings. The overall impact of 3DBio lies in its potential to transform patient-specific treatments through innovative tissue engineering solutions.
